Journal Article
. 2018 Jan; 73(6):1254-1262.
doi: 10.1111/all.13392.

Lolium perenne peptide immunotherapy is well tolerated and elicits a protective B-cell response in seasonal allergic rhinitis patients

R Mösges 1 A F Koch 1 E Raskopf 1 J Singh 1 K Shah-Hosseini 1 A Astvatsatourov 1 B Hauswald 2 Y Yarin 2 F Corazza 3 L Haazen 4 S Pirotton 4 S Allekotte 1 G Zadoyan 1 T Legon 4 S R Durham 5 M H Shamji 5 
Affiliations
  • PMID: 29322510
  •     34 References
  •     6 citations

Abstract

Background: Systemic allergic reactions are a risk for allergen immunotherapy that utilizes intact allergen preparations. We evaluated the safety, efficacy and immune mechanisms of short-course treatment with adjuvant-free Lolium perenne peptides (LPP) following a 6-week dose-escalation protocol.

Methods: In a prospective, dose-escalation study, 61 grass pollen-allergic patients received 2 subcutaneous injections of LPP once weekly for 6 weeks. Safety was assessed evaluating local reactions, systemic reactions and adverse events. The clinical effect of LPP was determined by reactivity to the conjunctival provocation test (CPT). Specific IgE, IgG4 and blocking antibodies were measured at baseline (V1), during (V6) and after treatment (V8).

Results: No fatality, serious adverse event or epinephrine use was reported. Mean wheal diameters after injections were <0.6 cm and mean redness diameters <2.5 cm, independent of dose. Transient and mostly mild adverse events were reported in 33 patients. Two patients experienced a grade I and 4 patients a grade II reaction (AWMF classification). At V8, 69.8% of patients became nonreactive to CPT. sIgG4 levels were higher at V6 (8.1-fold, P < .001) and V8 (12.2-fold, P < .001) than at V1. The sIgE:sIgG4 ratio decreased at V6 (-54.6%, P < .001) and V8 (-71.6%, P < .001) compared to V1. The absolute decrease in IgE-facilitated allergen binding was 18% (P < .001) at V6 and 25% (P < .001) at V8.

Conclusion: Increasing doses of subcutaneous LPP appeared safe, substantially diminished reactivity to CPT and induced blocking antibodies as early as 4 weeks after treatment initiation. The benefit/risk balance of LPP immunotherapy remains to be further evaluated in large studies.

Keywords: allergen; grass pollen peptides; safety; subcutaneous immunotherapy; tolerability.

Efficacy of 2 months of allergen-specific immunotherapy with Bet v 1-derived contiguous overlapping peptides in patients with allergic rhinoconjunctivitis: Results of a phase IIb study.
François Spertini, Gilles DellaCorte, +6 authors, Christophe Reymond.
J Allergy Clin Immunol, 2016 Jul 05; 138(1). PMID: 27373329
Objectifying the conjunctival provocation test: photography-based rating and digital analysis.
S Dogan, A Astvatsatourov, +4 authors, R Mösges.
Int Arch Allergy Immunol, 2013 Nov 20; 163(1). PMID: 24248100
Risk factors for adverse systemic reactions occurring during immunotherapy with standardized Dermatophagoides farinae extracts.
Y Ohashi, Y Nakai, +5 authors, Y Nasako.
Acta Otolaryngol Suppl, 1999 Jan 08; 538. PMID: 9879410
Negative clinical results from a randomised, double-blind, placebo-controlled trial evaluating the efficacy of two doses of immunologically enhanced, grass subcutaneous immunotherapy despite dose-dependent immunological response.
Jörg Kleine-Tebbe, Mikkel Walmar, +4 authors, Fernando Rodriguez.
Clin Drug Investig, 2014 Jul 06; 34(8). PMID: 24997093
Exploratory study of tolerability and immunological effect of a short up-dosing immunotherapy phase with a standardised allergen extract derived from pollen of Olea europaea.
Carmen Moreno, Blanca Sáenz De San Pedro, +3 authors, Fernando Florido.
Clin Transl Allergy, 2015 Jul 28; 5. PMID: 26213608    Free PMC article.
[Cluster-immunotherapy in seasonal allergic rhinitis: safety aspects of induction therapy with depot allergoids (Purethal)].
I Hansen, K Hörmann, +3 authors, L Klimek.
Laryngorhinootologie, 2003 Aug 14; 82(8). PMID: 12915987
The rate of systemic reactions to immunotherapy injections is the same whether or not the dose is reduced after a local reaction.
John M Kelso.
Ann Allergy Asthma Immunol, 2004 Mar 03; 92(2). PMID: 14989390
Specific subcutaneous immunotherapy with recombinant grass pollen allergens: first randomized dose-ranging safety study.
L Klimek, P Schendzielorz, R Pinol, O Pfaar.
Clin Exp Allergy, 2012 Aug 23; 42(6). PMID: 22909165
Immunologic effect and tolerability of intra-seasonal subcutaneous immunotherapy with an 8-day up-dosing schedule to 10,000 standardized quality-units: a double-blind, randomized, placebo-controlled trial.
Oliver Pfaar, Hendrik Wolf, +2 authors, Eike Wüstenberg.
Clin Ther, 2012 Oct 16; 34(10). PMID: 23063373
Patterns of pollen cross-allergenicity.
Richard W Weber.
J Allergy Clin Immunol, 2003 Aug 05; 112(2). PMID: 12897724
Review.
Immunological comparison of allergen immunotherapy tablet treatment and subcutaneous immunotherapy against grass allergy.
K Aasbjerg, V Backer, +5 authors, P A Würtzen.
Clin Exp Allergy, 2014 Apr 16; 44(3). PMID: 24734285
Safety of allergen-specific immunotherapy. Relation between dosage regimen, allergen extract, disease and systemic side-effects during induction treatment.
M T Mellerup, G W Hahn, L K Poulsen, H Malling.
Clin Exp Allergy, 2000 Sep 21; 30(10). PMID: 10998019
Position paper: Immunotherapy.
Allergy, 1993 Jan 01; 48(14 Suppl). PMID: 8342741
Lolium perenne peptide immunotherapy is well tolerated and elicits a protective B-cell response in seasonal allergic rhinitis patients.
R Mösges, A F Koch, +13 authors, M H Shamji.
Allergy, 2018 Jan 13; 73(6). PMID: 29322510    Free PMC article.
The IgE-facilitated allergen binding (FAB) assay: validation of a novel flow-cytometric based method for the detection of inhibitory antibody responses.
Mohamed H Shamji, Louisa K Wilcock, +6 authors, James N Francis.
J Immunol Methods, 2006 Oct 31; 317(1-2). PMID: 17070537    Free PMC article.
Fel d 1-derived peptide antigen desensitization shows a persistent treatment effect 1 year after the start of dosing: a randomized, placebo-controlled study.
Deepen Patel, Peter Couroux, +4 authors, Roderick P Hafner.
J Allergy Clin Immunol, 2012 Sep 18; 131(1). PMID: 22981787
Sublingual Immunotherapy for Allergic Rhinitis: Is 2-Year Treatment Sufficient for Long-term Benefit?
Linda S Cox.
JAMA, 2017 Feb 15; 317(6). PMID: 28196239
Risks and benefits of allergen immunotherapy.
Barbara Rogala, Joanna Glück.
Expert Opin Drug Saf, 2009 May 13; 8(3). PMID: 19432555
Functional rather than immunoreactive levels of IgG4 correlate closely with clinical response to grass pollen immunotherapy.
M H Shamji, C Ljørring, +8 authors, S R Durham.
Allergy, 2011 Nov 15; 67(2). PMID: 22077562
Specific Characteristics in Digital Assessment of Conjunctival Redness.
Anatoli Astvatsatourov, Ralph Mösges.
Stud Health Technol Inform, 2017 Jul 07; 238. PMID: 28679918
Standards for practical allergen-specific immunotherapy.
E Alvarez-Cuesta, J Bousquet, +4 authors, EAACI, Immunotherapy Task Force.
Allergy, 2006 Aug 26; 61 Suppl 82. PMID: 16930249
Conjunctival provocation tests: a predictive factor for patients' seasonal allergic rhinoconjunctivitis symptoms.
Kristian Kruse, Eva Gerwin, +2 authors, Ralph Mösges.
J Allergy Clin Immunol Pract, 2015 Jan 23; 3(3). PMID: 25609338
A high polymerized grass pollen extract is efficacious and safe in a randomized double-blind, placebo-controlled study using a novel up-dosing cluster-protocol.
L Klimek, J Uhlig, +2 authors, O Pfaar.
Allergy, 2014 Aug 19; 69(12). PMID: 25130503    Free PMC article.
Regulatory environment for allergen-specific immunotherapy.
S Kaul, S May, D Lüttkopf, Stefan Vieths.
Allergy, 2011 Feb 04; 66(6). PMID: 21288251
Review.
Allergen-specific immunotherapy with recombinant grass pollen allergens.
Marek Jutel, Lothar Jaeger, +3 authors, Oliver Cromwell.
J Allergy Clin Immunol, 2005 Sep 15; 116(3). PMID: 16159631
World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects.
World Medical Association.
JAMA, 2013 Oct 22; 310(20). PMID: 24141714
Highly Cited.
EAACI: A European Declaration on Immunotherapy. Designing the future of allergen specific immunotherapy.
Moises A Calderon, Pascal Demoly, +43 authors, Nikolaos Papadopoulos.
Clin Transl Allergy, 2012 Nov 01; 2(1). PMID: 23110958    Free PMC article.
Allergic rhinitis and its impact on asthma.
J Bousquet, P Van Cauwenberge, +2 authors, World Health Organization.
J Allergy Clin Immunol, 2001 Nov 15; 108(5 Suppl). PMID: 11707753
Highly Cited. Review.
Efficacy and safety of specific immunotherapy with SQ allergen extract in treatment-resistant seasonal allergic rhinoconjunctivitis.
Anthony J Frew, Richard J Powell, +2 authors, UK Immunotherapy Study Group.
J Allergy Clin Immunol, 2006 Feb 08; 117(2). PMID: 16461133
Allergen immunotherapy on the way to product-based evaluation-a WAO statement.
Claus Bachert, Mark Larché, +7 authors, Giovanni Passalacqua.
World Allergy Organ J, 2015 Sep 30; 8(1). PMID: 26417398    Free PMC article.
Comparison of conjunctival and nasal provocation test in allergic rhinitis to house dust mite.
Herbert Riechelmann, Barbara Epple, Gunther Gropper.
Int Arch Allergy Immunol, 2003 Feb 11; 130(1). PMID: 12576735
[Acute therapy of anaphylactoid reactions. Results of an intradisciplinary consensus conference].
F W Ahnefeld, J Barth, +7 authors, H H Mehrkens.
Anaesthesist, 1994 Apr 01; 43(4). PMID: 8179171
Review.
Lolium perenne peptides for treatment of grass pollen allergy: A randomized, double-blind, placebo-controlled clinical trial.
Mohamed H Shamji, Jan Ceuppens, +8 authors, Sabine Pirotton.
J Allergy Clin Immunol, 2017 Oct 17; 141(1). PMID: 29030102
Predicting patients at high-risk of systemic reactions to cluster allergen immunotherapy: a pilot prospective observational study.
J L Justicia, M J Barasona, +2 authors, F Guerra.
J Investig Allergol Clin Immunol, 2007 Dec 20; 17(6). PMID: 18088021
Lolium perenne peptide immunotherapy is well tolerated and elicits a protective B-cell response in seasonal allergic rhinitis patients.
R Mösges, A F Koch, +13 authors, M H Shamji.
Allergy, 2018 Jan 13; 73(6). PMID: 29322510    Free PMC article.
Two years of treatment with the recombinant grass pollen allergy vaccine BM32 induces a continuously increasing allergen-specific IgG4 response.
Julia Eckl-Dorna, Milena Weber, +12 authors, Verena Niederberger.
EBioMedicine, 2019 Dec 02; 50. PMID: 31786130    Free PMC article.
EAACI Allergen Immunotherapy User's Guide.
Montserrat Alvaro-Lozano, Cezmi A Akdis, +28 authors, Marta Vazquez-Ortiz.
Pediatr Allergy Immunol, 2020 May 22; 31 Suppl 25. PMID: 32436290    Free PMC article.
Review.
Mechanisms of Allergen Immunotherapy in Allergic Rhinitis.
Gabija Drazdauskaitė, Janice A Layhadi, Mohamed H Shamji.
Curr Allergy Asthma Rep, 2020 Dec 15; 21(1). PMID: 33313967    Free PMC article.
Review.
Novel vaccines for allergen-specific immunotherapy.
Oluwatoyin Akinfenwa, Azahara Rodríguez-Domínguez, +2 authors, Raffaela Campana.
Curr Opin Allergy Clin Immunol, 2020 Dec 29; 21(1). PMID: 33369572    Free PMC article.
Past, present, and future of allergen immunotherapy vaccines.
Yulia Dorofeeva, Igor Shilovskiy, +11 authors, Rudolf Valenta.
Allergy, 2020 Apr 07; 76(1). PMID: 32249442    Free PMC article.
Review.